http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Usio Enters into Exclusive Contract with Leading Crypto Brokerage - Voyager Digital Holdings
-
Voyager Digital Announces Listing Of The Elrond (EGLD) Gold Token
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Voyager (VYGR) announces FDA has notified Neurocrine (NBIX) that it has placed clinical hold on RESTORE-1 clinical trial of NBIb-1817
-
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
-
Voyager Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates
-
Voyager Therapeutics (VYGR) Announces IND Submission for VY-HTT01 Program Was Placed on Clinical Hold
-
Voyager Therapeutics Provides Regulatory Update on VY-HTT01 Program
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Voyager Therapeutics (VYGR) Announces Nancy Vitale to Board
-
Voyager Therapeutics Appoints Nancy Vitale to its Board of Directors
-
Voyager Therapeutics Appoints Michelle Quinn Smith as Chief Human Resources Officer
-
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor F
-
Neurocrine Bio (NBIX), Voyager (VYGR) Present New L-T 3-Year Data Demonstrating that One-Time Treatment with Investigational Gene Therapy Showed Sustained Improvement in Motor Function
-
Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor F
-
Voyager Therapeutics Announces Upcoming Presentations at the International Parkinson and Movement Disorder Society Virtual Congress 2020
-
Voyager Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates
-
Voyager Therapeutics to Report Second Quarter 2020 Financial Results and Participate in Upcoming Investor Conferences
-
Voyager Therapeutics Provides Update on AbbVie Vectorized Antibody Collaborations
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Voyager Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates
-
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2020 Annual Meeting
-
Voyager Therapeutics (VYGR) Provides Update on RESTORE-1 Parkinson’s Disease Trial
-
Voyager Therapeutics Provides Update on the RESTORE-1 Parkinson’s Disease Trial
-
Voyager Therapeutics Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference
-
Voyager Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates
-
Voyager Therapeutics to Participate in Upcoming Investor Conferences
-
Voyager Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates on March 3, 2020
-
Voyager Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Highlights
-
Voyager Therapeutics to Present at the Credit Suisse Healthcare Conference
-
Voyager Therapeutics to Host Third Quarter 2019 Financial Results and Corporate Highlights Conference Call
-
Voyager Digital Vastly Increases its Market by Releasing New Crypto Broker and Trading App for Android
-
Voyager Therapeutics to Present at Upcoming Investor Conferences in October 2019
-
Voyager Therapeutics to Present at Upcoming Investor Conferences in September 2019
-
Voyager Therapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights
-
Voyager Therapeutics to Host Second Quarter 2019 Financial Results and Corporate Highlights Conference Call
-
Voyager Therapeutics to Present at Upcoming Investor Conferences in August 2019
-
Voyager Therapeutics (VYGR) Reports Restructured Gene Therapy Relationship with Sanofi (SNY) Genzyme; Provides Portfolio Update
-
Voyager Therapeutics Announces Restructured Gene Therapy Relationship with Sanofi Genzyme and Portfolio Update
-
Voyager Therapeutics to Present at the Raymond James Life Sciences & MedTech Conference
-
Voyager Therapeutics (VYGR) announces retirement of Dinah Sah, Ph.D. as chief scientific officer
-
Voyager Therapeutics Announces Management Updates
-
Voyager Therapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights
-
Neurocrine Biosciences (NBIX), Voyager Therapeutics, Inc. (VYGR) Report Phase I Results for VY-AADC in Patients with Parkinson's Disease at AAN 2019 Meetings
-
Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting
-
Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson’s Disease at the American Academy of Neurology Annual Meeting
-
Voyager Therapeutics Announces New Data in Multiple Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting
-
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c)(4)
-
Voyager Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

